Oxycyte
Encyclopedia
Oxycyte is a third-generation perfluorocarbon (PFC) therapeutic oxygen
carrier invented by Leland Clark
and developed by Oxygen Biotherapeutics, Inc.(OBI) (formerly Synthetic Blood International). It is designed to enhance oxygen delivery to damaged tissues.
Because Oxycyte is a PFC, and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products; there have been no adverse events in company clinical trials that were related to Oxycyte. OBI believes that Oxycyte has a very favorable risk-benefit profile for its potential indications.
OBI has received approval from Swissmedic and the Israeli Ministry of Health to conduct a Phase II, dose escalation, clinical trial in Switzerland and Israel using Oxycyte as an emergency treatment in traumatic brain injury.
The company promotes Oxycyte as having potential for use in multiple indications, including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetic wounds and ulcers and cosmetic applications.
has been completed successfully. The company has received approval from Swissmedic and the Israeli Ministry of Health to begin a Phase II, dose escalation, clinical trial in Switzerland and Israel for use of Oxycyte as an emergency treatment for traumatic brain injury (TBI). The Insel Hospital in Berne will be the first of the planned seven trial centers in Switzerland and four in Israel to begin enrolling patients. The other trial centers planned for the Swiss study are in Zurich, Aarau, St. Gallen, Basel, Geneva and Lausanne.
Oxycyte is also the basis of a product to accelerate the healing of wounds by supplying oxygen to injured tissue from the outside in.
The company has conducted safety studies and plans an FDA filing for clinical trials related to this indication in late 2009.
Oxygen
Oxygen is the element with atomic number 8 and represented by the symbol O. Its name derives from the Greek roots ὀξύς and -γενής , because at the time of naming, it was mistakenly thought that all acids required oxygen in their composition...
carrier invented by Leland Clark
Leland Clark
Leland C. Clark Jr. was an American biochemist born in Rochester, New York. He is most well known as the inventor of the Clark electrode, a device used for measuring oxygen in blood, water and other liquids. Clark is considered the "Father of Biosensors", and the modern-day glucose sensor used...
and developed by Oxygen Biotherapeutics, Inc.(OBI) (formerly Synthetic Blood International). It is designed to enhance oxygen delivery to damaged tissues.
Product
When used as an intravenous emulsion, Oxycyte can carry as much as five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal. Like all PFC-based products, Oxycyte is not a complete blood substitute.Because Oxycyte is a PFC, and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products; there have been no adverse events in company clinical trials that were related to Oxycyte. OBI believes that Oxycyte has a very favorable risk-benefit profile for its potential indications.
OBI has received approval from Swissmedic and the Israeli Ministry of Health to conduct a Phase II, dose escalation, clinical trial in Switzerland and Israel using Oxycyte as an emergency treatment in traumatic brain injury.
The company promotes Oxycyte as having potential for use in multiple indications, including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetic wounds and ulcers and cosmetic applications.
Chemical Properties
The drug substance in Oxycyte is F-tert-butylcyclohexane, a saturated alicyctic PFC (molecular formula C10F20.Treatment of Traumatic Brain Injury
A Phase II-a clinical safety trial with Oxycyte in Traumatic Brain InjuryTraumatic brain injury
Traumatic brain injury , also known as intracranial injury, occurs when an external force traumatically injures the brain. TBI can be classified based on severity, mechanism , or other features...
has been completed successfully. The company has received approval from Swissmedic and the Israeli Ministry of Health to begin a Phase II, dose escalation, clinical trial in Switzerland and Israel for use of Oxycyte as an emergency treatment for traumatic brain injury (TBI). The Insel Hospital in Berne will be the first of the planned seven trial centers in Switzerland and four in Israel to begin enrolling patients. The other trial centers planned for the Swiss study are in Zurich, Aarau, St. Gallen, Basel, Geneva and Lausanne.
Topical and Wound Care Applications
OBI has incorporated Oxycyte into a gel, Dermacyte, for use in topical applications for the over-the-counter cosmetics market. It delivers concentrated oxygen to the skin. It is scheduled for retail sale in 2011Oxycyte is also the basis of a product to accelerate the healing of wounds by supplying oxygen to injured tissue from the outside in.
The company has conducted safety studies and plans an FDA filing for clinical trials related to this indication in late 2009.
External links
- Oxycyte Official Website Oxygen Biotherapeutics, Inc. product page.
- "Blood Simple" (Flash video) Wired ScienceWIRED ScienceWired Science is a weekly high-definition television program that covers modern scientific and technological topics. In January 2007 PBS aired pilot episodes for three different science programs, including Wired Science. Using Nielsen ratings, CPB-sponsored research and public feedback, PBS...
, October 31, 2007. pbs.org; Public Broadcasting ServicePublic Broadcasting ServiceThe Public Broadcasting Service is an American non-profit public broadcasting television network with 354 member TV stations in the United States which hold collective ownership. Its headquarters is in Arlington, Virginia....